Literature DB >> 22069087

Risk factors for elevated INR values during warfarin therapy in hospitalized pediatric patients.

Brady S Moffett1, Meng Ung, Lisa Bomgaars.   

Abstract

BACKGROUND: There are currently no data describing the incidence of or risk factors for elevated International Normalized Ratio (INR) values in patients receiving warfarin at a tertiary care pediatric hospital. By minimizing risk factors for elevated INR values patient morbidity may be minimized. PROCEDURES: A 6-year retrospective chart review of inpatient admissions at our institution that received warfarin was performed. Factors for elevated INR values, such as patient demographics, disease state, and medication interactions were reviewed. Patients with an INR value ≥ 0.5 above the upper limit of the goal range were compared to patients without an elevated INR value. A logistic regression analysis was performed to identify independent variables for elevated INR values.
RESULTS: A total of 298 patient admissions (184 patients) met study criteria, and the largest patient population was between 1 and 12 years old (36.9%). The most common indication for warfarin was mitral valve replacement (25.5%). An elevated INR occurred in 20.8% of admissions. Logistic regression analysis identified Asian race, an elevated baseline INR value, warfarin initiation after cardiac surgery, days of inpatient warfarin therapy, and drug interactions with ciprofloxacin and lansoprazole as independent variables for an elevated INR value (P < 0.05). Obesity was significant as an independent variable for a non-elevated INR value (P < 0.05).
CONCLUSIONS: Elevated INR values occur often in patients receiving warfarin while admitted to a tertiary care pediatric facility and modifiable risk factors exist for elevated INR values.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22069087     DOI: 10.1002/pbc.23308

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  5 in total

Review 1.  Racial and Ethnic Disparities in Adverse Drug Events: A Systematic Review of the Literature.

Authors:  Avi Baehr; Juliet C Peña; Dale J Hu
Journal:  J Racial Ethn Health Disparities       Date:  2015-03-24

2.  Warfarin-Rifampin Drug Interaction in a Pediatric Patient.

Authors:  Michael Poon; Brady S Moffett; Donald L Yee
Journal:  J Pediatr Pharmacol Ther       Date:  2017 Sep-Oct

3.  Warfarin anticoagulation after congenital heart surgery at a large children's hospital.

Authors:  Adam W Lowry; Brady S Moffett; Douglas Moodie; Jarrod D Knudson
Journal:  Pediatr Cardiol       Date:  2012-05-16       Impact factor: 1.655

4.  Determining risk factors of bleeding in patients on warfarin treatment.

Authors:  Evren Uygungül; Cuneyt Ayrik; Huseyin Narci; Semra Erdoğan; Ibrahim Toker; Filiz Demir; Ulas Karaaslan
Journal:  Adv Hematol       Date:  2014-11-09

5.  Characterizing variability in warfarin dose requirements in children using modelling and simulation.

Authors:  Anna-Karin Hamberg; Mia Wadelius; Lena E Friberg; Tina T Biss; Farhad Kamali; E Niclas Jonsson
Journal:  Br J Clin Pharmacol       Date:  2014-07       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.